Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02034201 · ClinicalTrials.gov registry record · Phase 1
Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02034201 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 19 participants.
The verdict
NCT02034201, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Methamphetamine dependence is a serious public health problem, with methamphetamine abusers being at risk for significant morbidity and mortality, including HIV. To date, no medication or psychotherapeutic strategy has shown robust, long-term efficacy in treating this disorder. This clinical trial will examine whether lisdexamfetamine shows promise in alleviating withdrawal symptoms and preventing relapse relative to placebo in recently-abstinent methamphetamine dependent individuals. Findings of this study will not only shed light on whether lisdexamfetamine may improve upon treatment for this disorder but also inform future medication development strategies for improving treatment for drug dependence disorders. Discovering efficacious limited risk interventions that show more robust, longer-term outcomes would be beneficial both to the individual and society.
Interventions
- DRUG Placebo
- DRUG Lisdexamfetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02034201
The ClinicalTrials.gov registry entry for NCT02034201 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02034201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02034201 about?
NCT02034201 is a clinical study titled "Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence". Methamphetamine dependence is a serious public health problem, with methamphetamine abusers being at risk for significant morbidity and mortality, including HIV. To date, no medication or psychotherapeutic strategy has shown robust, long-term efficacy in treating this disorder. This clinical trial w...
What is the current status of trial NCT02034201?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-02. Estimated completion is 2016-05-19.
What interventions are being tested in trial NCT02034201?
The interventions under investigation include: Placebo (DRUG), Lisdexamfetamine (DRUG).
Who is sponsoring clinical trial NCT02034201?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.